Monopar Therapeutics
Monopar Therapeutics reported revenue of $0 million in fiscal 2025. It paid out $35 million in dividends and buybacks. The diluted share count rose 95.5%.
Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
What Monopar Therapeutics does
Monopar Therapeutics is a clinical-stage drug company, so it has no approved products. It is developing a treatment for Wilson disease and new radiopharmaceuticals for cancer. Radiopharmaceuticals are drugs that carry radioactive material to find or destroy tumor cells.
Its Wilson disease candidate is ALXN1840, a once-daily pill in late-stage development. Wilson disease is a rare genetic condition in which the body can't remove excess copper, which builds up in the liver and brain. ALXN1840 has Orphan Drug Designation in the U.S. and the EU and Fast Track designation. The company says its near-term focus is putting together a regulatory package and submitting a new drug application to the FDA.
Its cancer programs, MNPR-101-Zr, MNPR-101-Lu and MNPR-101-Ac, target a protein called uPAR found on some advanced cancers. They are at the imaging, early human-trial and late preclinical stages. Monopar builds its pipeline by research of its own and by licensing drugs from others, and it recently acquired the ALXN1840 program.
Its biggest risks, as it describes them
- A short operating history, large expected losses and a high risk of never being profitable.
- It may need more funding or pharmaceutical partners to continue its clinical programs.
- Its recently acquired ALXN1840 program could face delays in development or in gaining approval.
- Market conditions, including inflation, tariffs and geopolitical events, could affect its costs and its ability to raise money.
Income statement
Monopar Therapeutics lost money in fiscal 2025: a net loss of $14 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 20 | 12 | 14 | 91 | 123 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 13.0x | 4.2x | 4.2x | 11.5x | 51.4x |
| Quick ratio | 13.0x | 4.2x | 4.2x | 11.5x | 51.4x |
Cash flow
Free cash flow is cash from operations minus capital expenditure. The SEC's structured data for Monopar Therapeutics' filings doesn't give both for any year, so free cash flow is left out.
Projections
Project Monopar Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 1 insider bought $104,925 of Monopar Therapeutics shares on the open market, and 5 insiders sold $3.7 million, $3.4 million of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 24, 2026 | Chandler RobinsonChief Executive Officer, Director | Sold plan | 29,056 | $88.00 | $2.6 million | Form 4 |
| Aug 26, 2026 | Kim R TsuchimotoDirector | Sold plan | 4,090 | $111.39 | $455,567 | Form 4 |
| Aug 26, 2026 | Patrice RiouxActing Chief Medical Officer | Sold plan | 1 | $111.26 | $111 | Form 4 |
| Aug 25, 2026 | Raymond AndersonDirector | Sold plan | 3,142 | $111.77 | $351,189 | Form 4 |
| Dec 26, 2025 | Quan Anh VuChief Financial Officer | Bought | 1,500 | $69.95 | $104,925 | Form 4 |
| Dec 18, 2025 | Arthur J KlausnerDirector | Sold | 5,121 | $67.15 | $343,889 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | — | — |
| Altman Z'' | −26.48 | 11.09 | 53.62 |
| Accruals ratio | −5.3% | −27.1% | −1.5% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Fail | Fail | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Pass | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | — | Fail |
| F-score | — | — | — |
Compare
Put Monopar Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Monopar Therapeutics | FY25 | — | — | — | — | — | — | |
| Aardvark Therapeutics | FY25 | — | — | — | — | — | — | Compare |
| ABVC BioPharma | FY25 | −41.9% | −2,416.0% | — | — | — | — | Compare |
| Acadia Pharmaceuticals | FY25 | 11.9% | 9.8% | 9.8% | — | — | — | Compare |
| Aclaris Therapeutics | FY25 | −58.2% | −975.9% | −603.4% | — | — | — | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 0 | 0 | 0 | 0 | — | — | — | — | 0 | 0 |
| Revenue growth | — | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | 0 | 1 | 2 | 2 | 4 | 6 | 8 | 6 | 13 | 10 |
| Operating income | −1 | −17 | −3 | −4 | −6 | −9 | −10 | −9 | −16 | −17 |
| Net income | −1 | −17 | −3 | −4 | −6 | −9 | −10 | −8 | −16 | −14 |
| Diluted EPS (US$) | — | −9.45 | −1.75 | −2.25 | −2.90 | −3.65 | — | — | — | — |
| Diluted shares (millions) | — | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 4 | 7 |
| Cash flow | ||||||||||
| Cash from operations | −1 | −3 | −3 | −3 | −5 | −7 | −7 | −8 | −6 | −12 |
| Capital expenditure | — | — | — | — | — | — | — | — | — | — |
| Free cash flow | — | — | — | — | — | — | — | — | — | — |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 35 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 0 | 0 | 0 | 1 | 1 | 2 | 2 | 2 | 1 | 5 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 2 | 9 | 7 | 13 | 17 | 20 | 12 | 14 | 91 | 123 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 3 | 10 | 7 | 13 | 17 | 20 | 13 | 7 | 60 | 141 |
| Total liabilities | 0 | 0 | 0 | 1 | 1 | 2 | 3 | 2 | 5 | 3 |
| Shareholders' equity | 3 | 10 | 7 | 13 | 16 | 19 | 10 | 6 | 55 | 138 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — | — | — |
| Free cash flow margin | — | — | — | — | — | — | — | — | — | — |
| Rule of 40 (growth + FCF margin) | — | — | — | — | — | — | — | — | — | — |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | — | −265.9% | −39.0% | −43.2% | −44.5% | −52.6% | −72.4% | −107.2% | −51.4% | −14.2% |
| Return on assets | — | −258.1% | −37.4% | −40.9% | −41.7% | −48.7% | −62.3% | −81.7% | −46.1% | −13.7% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |